Anti-VEGF agents have forced us to choose an agent and regimen, and learn when enough is enough.
A closer look at five abstracts on VMT, DME, AMD, OCT and gene therapy.
A conversation on the nuances of implementing treat and extend.
Now that we have OCT-A, we can no longer ignore macular neovascularization in non-exudative AMD.
Gathering and analyzing imaging biomarkers from SD-OCT along with other inputs can aid in tracking patients.
What we know and don’t know about geographic atrophy.
Lead investigator provides details on parallel trials of lampalizumab.
A host of trials are trying to answer this question. Here’s what they’ve found so far.